![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
GS-9350: A Pharmacoenhancer Without anti-HIV Activity
|
|
|
Reported by Jules Levin
CROI Feb 7-12 2009
Montreal, Canada
AA Mathias, P German, M Lee, C Callebaut, L Xu, L Tsai, B Murray, H Liu,
K Yale, D Warren and BP Kearney
Gilead Sciences
Foster City, CA, USA
AUTHOR CONCLUSIONS
-- GS-9350 is a potent, selective, mechanism-based CYP3A inhibitor that lacks anti-HIV activity and has limited effects on adipocyte function in vitro
-- GS-9350 boosts CYP3A substrates comparable to RTV in humans
-- EVG/FTC/TDF/GS-9350 FDC tablet achieves desired exposures of EVG, FTC and TFV
![summary-1.gif](../images/021109/summary-1.gif)
![keyPham-2.gif](../images/021109/keyPham-2.gif)
![Fold-3.gif](../images/021109/Fold-3.gif)
![study-4.gif](../images/021109/study-4.gif)
![PK-5.gif](../images/021109/PK-5.gif)
![FTCC-6.gif](../images/021109/FTCC-6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|